Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature.

Kirchhoff TD, Mittendorf T, Schmidt RE, Jablonka A, Merkesdal S.

Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):307-17. doi: 10.1586/erp.12.19. Review.

PMID:
22812555
2.

A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.

Tran-Duy A, Boonen A, van de Laar MA, Franke AC, Severens JL.

Ann Rheum Dis. 2011 Dec;70(12):2111-8. doi: 10.1136/annrheumdis-2011-200333. Epub 2011 Aug 20.

PMID:
21857027
3.

The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.

Kobelt G, Andlin-Sobocki P, Maksymowych WP.

J Rheumatol. 2006 Apr;33(4):732-40.

PMID:
16583476
4.

An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D.

Ann Rheum Dis. 2006 Dec;65(12):1620-5. Epub 2006 Feb 7.

5.

BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.

Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P; BSR Standards, Guidelines and Audit Working group.

Rheumatology (Oxford). 2005 Jul;44(7):939-47. Epub 2005 May 18. No abstract available.

PMID:
15901904
6.

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.

7.

TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Merkesdal S, Zeidler H.

Curr Rheumatol Rep. 2005 Aug;7(4):254-8. Review. No abstract available.

PMID:
16045826
8.

Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.

Neilson AR, Sieper J, Deeg M.

Rheumatology (Oxford). 2010 Nov;49(11):2122-34. doi: 10.1093/rheumatology/keq222. Epub 2010 Jul 26.

PMID:
20660498
9.

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J.

Rheumatology (Oxford). 2004 Sep;43(9):1158-66. Epub 2004 Jun 29.

PMID:
15226514
10.

The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.

Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.

Rheumatology (Oxford). 2005 Oct;44(10):1277-81. Epub 2005 Aug 16.

PMID:
16105913
11.

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.

Braun J, van der Heijde D.

Expert Opin Investig Drugs. 2003 Jul;12(7):1097-109. Review.

PMID:
12831346
12.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
13.

The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.

Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez E, Braun J.

Scand J Rheumatol. 2008 Jan-Feb;37(1):62-71. doi: 10.1080/03009740701607224.

PMID:
18189197
14.

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.

J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8.

PMID:
22115327
15.

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E.

Drugs. 2004;64(24):2793-811. Review.

PMID:
15563249
16.

Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study.

Cinar M, Dinc A, Simsek I, Erdem H, Koc B, Pay S, Kilic S.

Rheumatol Int. 2010 Jan;30(3):331-40. doi: 10.1007/s00296-009-0963-y. Epub 2009 May 23. Erratum in: Rheumatol Int. 2010 Jun;30(8):1141.

PMID:
19466421
17.

Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.

Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, van der Linden S.

Ann Rheum Dis. 2005 Mar;64(3):396-402. Epub 2004 Jul 22.

18.

Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.

Davis JC Jr.

Semin Arthritis Rheum. 2005 Feb;34(4):668-77. Review.

PMID:
15692960
19.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
20.

Management and treatment of ankylosing spondylitis.

Zochling J, Braun J.

Curr Opin Rheumatol. 2005 Jul;17(4):418-25. Review.

PMID:
15956838

Supplemental Content

Support Center